Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


In Brief: Chiron/Ortho v. Roche

This article was originally published in The Gray Sheet

Executive Summary

Chiron and immunodiagnostics partner Ortho Diagnostics Systems file patent infringement claims in the Northern District Court of California and in the District Court of The Hague, The Netherlands against Hoffmann La Roche alleging that Roche's hepatitis C polymerase chain reaction assays infringe Chiron's newly-issued U.S. patents 5,712,088 and 5,714,596, and its longer-standing European patent EP318,216. Both suits ask the courts to enjoin Roche from further sales of its HCV PCR tests and to pay Chiron/Ortho "unspecified damages," Chiron says. Previous HCV-related patent infringement suits brought by Chiron/Ortho resulted in settlements favoring Chiron/Ortho's European patent position. In September 1996, Chiron/Ortho and International Murex settled their patent dispute by entering a worldwide licensing agreement ("The Gray Sheet" Sept. 2, 1996, I&W-7). In October 1995, Organon Teknika agreed to stop selling its HCV assays in Europe and paid Chiron/Ortho a compensatory lump-sum payment for past infringement...

You may also be interested in...

Finance Watch: Silverback, Kinnate, Sigilon Launch December’s First IPOs

Public Company Edition: Lixte’s small uplisting was the only biopharma initial public offering in the US during Thanksgiving week, but IPOs are ramping up again. Also, LifeSci launched its second SPAC and in follow-on offerings Reata brought in $281m and Intellia grossed $175m.

BioCryst’s Oral Option To Take On Injectables In HAE Prophylaxis Market

Orladeyo is the first oral prophylactic approved in the US for hereditary angioedema, with Japan and EU approvals expected to follow. Pricing of $485,000 a year undercuts segment leader.

STRENGTH Results May Weaken Chances For Omega-3 Fatty Acid Heart Health Claims

Results of Study to Assess Statin Residual Risk with Epanova in High Cardiovascular Risk Patients with Hypertriglyceridemia “should prompt reconsideration of [OTC] mixed omega-3 fatty acid products for [atherosclerotic cardiovascular disease] prevention,” say cardiologists in an editorial published with JAMA study.




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts